{"id":"abbv-668","safety":{"commonSideEffects":[{"rate":"40-50%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting BTK, ABBV-668 disrupts B-cell receptor signaling, which is crucial for the survival and function of malignant B cells. This mechanism of action is particularly relevant in the treatment of certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia.","oneSentence":"ABBV-668 is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:17.401Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory mantle cell lymphoma"},{"name":"Relapsed or refractory marginal zone lymphoma"}]},"trialDetails":[{"nctId":"NCT05570006","phase":"PHASE2","title":"Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-03-16","conditions":"Ulcerative Colitis","enrollment":30},{"nctId":"NCT06477926","phase":"PHASE1","title":"A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-07-09","conditions":"Healthy Volunteers","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABBV-668","genericName":"ABBV-668","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABBV-668 is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK). Used for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}